This result is not nearly as sluggish as the market response suggests.
They booked significant costs, either for future growth (14% R&D increase and new product support +>increased 15% increase in staffing), or none-offs ($12m donation of product and $65m unfavourable forex move, taken above the line).
Most companies would have capitalised some of these expenses, but not CSL; they just expense them outright. Very conservative accounting for profits, which I like.
Ann: Appendix 4D and Half Year Accounts, page-9
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$278.11 |
Change
1.540(0.56%) |
Mkt cap ! $134.6B | |||
| Open | High | Low | Value | Volume |
| $278.10 | $278.65 | $276.24 | $94.21M | 338.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 44 | $277.88 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $278.30 | 216 | 1 |
View Market Depth
| Last trade - 16.10pm 23/12/2024 (20 minute delay) ? |
| CSL (ASX) Chart |
